Patrick Hwu

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 31 papers. Top paper: “Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity”.

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

Cancer Cell(2022)10.1016/j.ccell.2022.04.004

N/A

4.7DataRank · unranked

350 citations

Daniel H. Johnson, Noha Abdel‐Wahab, Wai Chin Foo, Salah-Eddine Bentebibel, May Daher +32 more

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

Science(2018)10.1126/science.aan4236

N/A

1.3DataRank · unranked

4585 citations

C. N. Spencer, Luigi Nezi, Alexandre Reuben, Miles C. Andrews, Tatiana V. Karpinets +89 more

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-006822

N/A

1.3DataRank · unranked

52 citations

Anne Knisely, David Vining, Scott Kopetz, Michael J. Overman, Milind Javle +16 more

B cells and tertiary lymphoid structures promote immunotherapy response

Nature(2020)10.1038/s41586-019-1922-8

N/A

1.2DataRank · unranked

2564 citations

Sangeetha M. Reddy, Jianjun Gao, Shaojun Zhang, Rafet Başar, Rohit Thakur +55 more

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Nature Medicine(2021)10.1038/s41591-021-01406-6

N/A

0.910DataRank · unranked

429 citations

Connie P. M. Duong, Vancheswaran Gopalakrishnan, Valerio Iebba, W. S. Chen, Lisa Derosa +66 more

Multi-modal molecular programs regulate melanoma cell state

Nature Communications(2022)10.1038/s41467-022-31510-1

N/A

0.812DataRank · unranked

26 citations

Junna Oba, Chang‐Jiun Wu, Haifeng Zhu, Tatiana V. Karpinets, Caitlin Creasy +31 more

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Cancer Immunology Research(2023)10.1158/2326-6066.cir-22-0444

N/A

0.656DataRank · unranked

14 citations

Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner +36 more

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

Journal of Translational Medicine(2022)10.1186/s12967-022-03450-3

N/A

0.614DataRank · unranked

12 citations

Sandra J. Lee, Aik Choon Tan, Issam M. El Naqa, F. Stephen Hodi, Lisa H. Butterfield +10 more

The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy

Frontiers in Immunology(2023)10.3389/fimmu.2023.1237715

N/A

0.500DataRank · unranked

27 citations

Xia Bu, Yunfei Wang, Michael R. Gomez, James A. Torchia, Ping Hua +7 more

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.08.31.506051

N/A

0.300DataRank · unranked

4 citations

Alvin Shi, Ming Tang, Marcus Ho, Christopher Terranova, Kyriaki Galani +36 more

LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade

Journal of Clinical Investigation(2022)10.1172/jci154152

N/A

0DataRank · unranked

44 citations

Joost Koetsier, Trevin Kurtanich, Michael Engelbrecht Nielsen, Glenn Winn, Yunfei Wang +25 more

Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2661

N/A

0DataRank · unranked

36 citations

Ashley V. Menk, Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu, Jun Li +47 more

Rethinking the immunotherapy numbers game

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005107

N/A

0DataRank · unranked

24 citations

Mohammad U. Zahid, Jennifer M. Binning, Bryan Q. Spring, Patrick Hwu, Shari Pilon‐Thomas +2 more

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-004310

N/A

0DataRank · unranked

19 citations

Sandra J. Lee, Aik Choon Tan, Issam M. El Naqa, F. Stephen Hodi, Lisa H. Butterfield +9 more

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration

(2022)10.52519/00101

N/A

0DataRank · unranked

3 citations

Yusra B. Medik, Bhakti K. Patel, Daniel B. Zamler, Sijie Chen, T. Chapman +39 more

Spatial PD‐L1, immune‐cell microenvironment, and genomic copy‐number alteration patterns and drivers of invasive‐disease transition in prospective oral precancer cohort

Cancer(2023)10.1002/cncr.34607

N/A

0DataRank · unranked

14 citations

Jianjun Zhang, Xin Zhao, Edwin R. Parra, Naohiro Uraoka, Heather Lin +16 more

Data from Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

(2023)10.1158/1535-7163.c.6531608

N/A

0DataRank · unranked

0 citations

Jonathan C. Trent, Katherine Stemke‐Hale, Alexander J. Lazar, Sabrina Pricl, Giovanni M. Pavan +11 more

Data from Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

(2023)10.1158/1535-7163.c.6531608.v1

N/A

0DataRank · unranked

0 citations

Jonathan C. Trent, Katherine Stemke‐Hale, Alexander J. Lazar, Sabrina Pricl, Giovanni M. Pavan +11 more

Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

(2023)10.1158/2159-8290.c.6549433.v1

N/A

0DataRank · unranked

0 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu‐Chin Fu +29 more

A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuvant ipilimumab (ipi) survival outcomes in patients (pts) with high-risk melanoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e21557

N/A

0DataRank · unranked

0 citations

Timothy I. Shaw, Sandra J. Lee, F. Stephen Hodi, Patrick Hwu, Dung‐Tsa Chen +7 more

Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers

Journal of Oncology Research and Therapy(2024)10.29011/2574-710x.10224

N/A

0DataRank · unranked

1 citations

Dale J. Hedges, Aik Choon Tan, Paulo C. Rodrı́guez, Vineeth Sukrithan, Aakrosh Ratan +10 more

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

Nature Communications(2025)10.1038/s41467-025-65016-3

N/A

0DataRank · unranked

5 citations

Tingyi Li, Islam Eljilany, Alex C. Soupir, Michael D. Radmacher, Phaedra Agius +17 more

Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapy

Research Square(2020)10.21203/rs.3.rs-58480/v1

N/A

0DataRank · unranked

0 citations

Christopher P. Vellano, Michael White, Miles C. Andrews, Joseph R. Daniele, Mark Titus +41 more

Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0331

N/A

0DataRank · unranked

73 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu-Chin Fu +29 more

Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer

Cancer Discovery(2021)10.1158/2159-8290.cd-20-1083

N/A

0DataRank · unranked

23 citations

Amir A. Jazaeri, Patrick Hwu, Samantha M. Fix

88 Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males

Regular and Young Investigator Award Abstracts(2021)10.1136/jitc-2021-sitc2021.088

N/A

0DataRank · unranked

1 citations

Aik Choon Tan, Issam El Naqa, Sandra Lee, F. Stephen Hodi, Lisa H. Butterfield +9 more

187 Multi-omic single-cell profiling demonstrates that competition for fatty acids and fatty acid oxidation enables tumor-infiltrating lymphocyte function and survival

Regular and Young Investigator Award Abstracts(2021)10.1136/jitc-2021-sitc2021.187

N/A

0DataRank · unranked

0 citations

Cara Haymaker, Jay R T. Adolacion, Xingyue An, Caitlin Creasy, Mohsen Fathi +10 more

87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-sitc2021.087

N/A

0DataRank · unranked

0 citations

Aik Choon Tan, Issam El Naqa, Sandra Lee, F. Stephen Hodi, Lisa H. Butterfield +8 more

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Nature(2022)10.1038/s41586-022-04833-8

N/A

0DataRank · unranked

130 citations

Michael G. White, Miles C. Andrews, Manoj Chelvanambi, Russell G. Witt, Joseph R. Daniele +60 more

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration

The Journal of Experimental Medicine(2022)10.1084/jem.20221333

N/A

0DataRank · unranked

64 citations

Yusra B. Medik, Bhakti Patel, Daniel Zamler, Sijie Chen, Thomas Chapman +39 more

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-003750

N/A

0DataRank · unranked

44 citations

Marie‐Andrée Forget, Donastas Sakellariou-Thompson, Yunfei Wang, Tamara Griffiths, Minjung Lee +10 more